The antimicrobial activity of the new nonribosomal peptide emericellipsin A against biofilm-forming, pathogenic, gram-positive and gram-negative clinical bacteria was studied. It was shown for the first time that peptides from the group of peptaibols can inhibit pathogenic forms of bacteria via their effect on biofilm formation. The most pronounced effect was demonstrated in relation to gram-positive bacteria.